T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SRGA
2776
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $177K | ﹤0.01% |
8,223
-417
| -5% | -$11.2K |
|
2777
N-able
NABL
$695M
| $176K | ﹤0.01% |
+15,822
| New | +$196K |
|
|
LOGC
2778
DELISTED
ContextLogic
LOGC
| $173K | ﹤0.01% |
1,851
+614
| +50% | +$81.4K |
|
2779
Acacia Research
ACTG
$449M
| $172K | ﹤0.01% |
33,595
-800
| -2% | -$4.32K |
|
2780
Clover Health Investments
CLOV
$2.38B
| $172K | ﹤0.01% |
46,317
+21,745
| +88% | +$133K |
|
2781
Greenlight Captial
GLRE
$512M
| $172K | ﹤0.01% |
21,877
-970
| -4% | -$7.12K |
|
|
SEI
2782
Solaris Energy Infrastructure
SEI
$3.94B
| $172K | ﹤0.01% |
26,307
-10,500
| -29% | -$77.8K |
|
|
MYOV
2783
DELISTED
Myovant Sciences Ltd.
MYOV
| $170K | ﹤0.01% |
+10,900
| New | +$208K |
|
2784
Westwater Resources
WWR
$75.2M
| $169K | ﹤0.01% |
78,400
+23,200
| +42% | +$70.9K |
|
|
TCRR
2785
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $169K | ﹤0.01% |
+36,281
| New | +$227K |
|
2786
Gevo
GEVO
$401M
| $168K | ﹤0.01% |
39,175
-50,535
| -56% | -$310K |
|
|
AIXC
2787
AIxCrypto Holdings Inc
AIXC
$14M
| $166K | ﹤0.01% |
309
+94
| +44% | +$56.5K |
|
2788
Ecovyst
ECVT
$1.1B
| $165K | ﹤0.01% |
16,138
-767
| -5% | -$8.39K |
|
2789
Purple Innovation
PRPL
$28.7M
| $165K | ﹤0.01% |
498
-726
| -59% | -$281K |
|
2790
VistaGen Therapeutics
VTGN
$11.8M
| $165K | ﹤0.01% |
2,812
+950
| +51% | +$61.8K |
|
2791
Cullinan Oncology
CGEM
$1.26B
| $164K | ﹤0.01% |
+10,627
| New | +$212K |
|
2792
Crescent Energy
CRGY
$3.93B
| $164K | ﹤0.01% |
+12,924
| New | +$179K |
|
2793
LifeVantage
LFVN
$81.9M
| $164K | ﹤0.01% |
25,900
| – | – |
|
|
ATRS
2794
DELISTED
Antares Pharma, Inc.
ATRS
| $162K | ﹤0.01% |
45,257
-3,200
| -7% | -$11.2K |
|
|
CHMI
2795
Cherry Hill Mortgage Investment Corp
CHMI
$108M
| $157K | ﹤0.01% |
19,030
| – | – |
|
|
BHR
2796
Braemar Hotels & Resorts
BHR
$139M
| $154K | ﹤0.01% |
30,130
-703
| -2% | -$3.45K |
|
2797
Vitamin Cottage Natural Grocers
NGVC
$646M
| $154K | ﹤0.01% |
10,809
-200
| -2% | -$2.56K |
|
|
NKLA
2798
DELISTED
Nikola Corporation Common Stock
NKLA
| $154K | ﹤0.01% |
519
-110
| -17% | -$36.7K |
|
2799
Rafael Holdings
RFL
$102M
| $153K | ﹤0.01% |
+30,350
| New | +$408K |
|
2800
CleanSpark
CLSK
$2.96B
| $152K | ﹤0.01% |
+15,974
| New | +$255K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.